U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. XYNTHA
  1. Approved Blood Products

STN: BL 125264
Proper Name: Antihemophilic Factor (Recombinant), Plasma/Albumin Free
Tradename: XYNTHA
Manufacturer: Wyeth Pahrmaceuticals, LLC
Indication: 

  • XYNTHA is a recombinant antihemophilic factor indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes.
  • XYNTHA is not indicated in patients with von Willebrand’s disease.

Product Information

Supporting Documents

Back to Top